Stock Events

Stock Events

Ultimovacs ASA 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2021
Q2 2026
Next
-1.47
-1.14
-0.81
-0.47
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-12.02MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BioNTech
BNTX
Mkt Cap26.06B
BioNTech SE is a competitor because it focuses on developing immunotherapies for cancer and other serious diseases, similar to Ultimovacs' focus on cancer vaccine development.
Moderna
MRNA
Mkt Cap58.11B
Moderna, Inc. is involved in creating mRNA-based therapies and vaccines, including for cancer, which competes with Ultimovacs' cancer vaccine research.
Novavax
NVAX
Mkt Cap1.69B
Novavax, Inc. competes in the vaccine space, including efforts in developing vaccines that could potentially overlap with Ultimovacs' cancer vaccine initiatives.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences, Inc. has a broad portfolio in oncology and immunotherapy, areas that are directly competitive with Ultimovacs' cancer treatment research.
AMGEN
AMGN
Mkt Cap236.38B
Amgen Inc. is a biotechnology company with a focus on cancer and human therapeutics, which competes with Ultimovacs' work in cancer vaccines.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol-Myers Squibb Company has a strong presence in cancer immunotherapy, making it a direct competitor to Ultimovacs' cancer vaccine development.
Merck
MRK
Mkt Cap370.89B
Merck & Co., Inc. is a leading company in cancer immunotherapy, particularly with its successful PD-1 inhibitor, competing in the same space as Ultimovacs.
Pfizer
PFE
Mkt Cap162.16B
Pfizer Inc. has a diverse portfolio including oncology and vaccine development, areas where it competes with Ultimovacs.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC has a strong focus on oncology, including immunotherapy and vaccines, making it a competitor to Ultimovacs.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its pharmaceutical division Janssen, is involved in developing treatments for various cancers, competing with Ultimovacs' cancer vaccine efforts.

About

Established in 2016 and headquartered in Oslo, Norway, Zelluna ASA specializes in the creation of T-cell receptor (TCR) cellular immunotherapy treatments aimed at combating solid tumors.
Show more...
CEO
Namir Hassan
Employees
15
Country
Other
ISIN
NO0010851603

Listings

ST
SE
ULTIO.ST
MU
DE
7UM.MU
OL
NO
ZLNA.OL
STU
DE
7UM0.STU

0 Comments

Share your thoughts

FAQ

What is Ultimovacs ASA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Ultimovacs ASA stocks are traded under the ticker 7UM.MU.
When is the next Ultimovacs ASA earnings date?▼
Ultimovacs ASA is going to release the next earnings report on November 05, 2026.
What is Ultimovacs ASA revenue for the last year?▼
Ultimovacs ASA revenue for the last year amounts to 0 EUR.
What is Ultimovacs ASA net income for the last year?▼
7UM.MU net income for the last year is -12.02M EUR.
How many employees does Ultimovacs ASA have?▼
As of September 09, 2026, the company has 15 employees.
In which sector is Ultimovacs ASA located?▼
Ultimovacs ASA operates in the Health & Wellness sector.
When did Ultimovacs ASA complete a stock split?▼
The last stock split for Ultimovacs ASA was on April 01, 2025 with a ratio of 1:10.
Where is Ultimovacs ASA headquartered?▼
Ultimovacs ASA is headquartered in Oslo, Other.